Thomas Vanwolleghem

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2668937/publications.pdf

Version: 2024-02-01

67 papers

3,546 citations

196777 29 h-index 58 g-index

67 all docs

67
docs citations

67 times ranked

4848 citing authors

#	Article	IF	Citations
1	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut, 2022, 71, 402-414.	6.1	39
2	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	2.4	42
3	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology, 2022, 162, 757-771.e4.	0.6	63
4	Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterology Journal, 2022, 10, 115-123.	1.6	6
5	Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV. JHEP Reports, 2022, 4, 100398.	2.6	10
6	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237
7	Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach. BMC Infectious Diseases, 2022, 22, 397.	1.3	3
8	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. Journal of Viral Hepatitis, 2021, 28, 431-435.	1.0	7
9	Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3. Frontiers in Microbiology, 2021, 12, 645020.	1.5	6
10	Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cellular Immunology, 2021, 362, 104283.	1.4	9
11	Treatment induced clearance of hepatitis E viruses by interferonâ€lambda in liverâ€humanized mice. Liver International, 2021, 41, 2866-2873.	1.9	7
12	The Viral ORF3 Protein Is Required for Hepatitis E Virus Apical Release and Efficient Growth in Polarized Hepatocytes and Humanized Mice. Journal of Virology, 2021, 95, e0058521.	1.5	9
13	Sexual Dimorphism in Hepatocyte Xenograft Models. Cell Transplantation, 2021, 30, 096368972110061.	1.2	2
14	2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting. Insights Into Imaging, 2021, 12, 145.	1.6	1
15	A rare case of hemodialysis-related portosystemic encephalopathy and review of the literature Acta Clinica Belgica, 2020, 75, 296-300.	0.5	1
16	Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis. Biomedicines, 2020, 8, 546.	1.4	2
17	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. Frontiers in Immunology, 2020, 11, 1711.	2.2	19
18	Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda. Journal of Hepatology, 2020, 73, 1271-1273.	1.8	2

#	Article	IF	CITATIONS
19	Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 467-490.	2.3	26
20	A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy. Clinical Biochemistry, 2020, 83, 86-88.	0.8	0
21	Stable HEV IgG seroprevalence in Belgium between 2006 and 2014. Journal of Viral Hepatitis, 2020, 27, 1253-1260.	1.0	4
22	Nivolumab and anti-HCV activity, a case report. Acta Clinica Belgica, 2020, 76, 1-5.	0.5	3
23	Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV. Journal of Hepatology, 2020, 73, 52-61.	1.8	33
24	A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochemical and Biophysical Research Communications, 2020, 524, 510-515.	1.0	9
25	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology, 2020, 159, 521-533.e9.	0.6	80
26	Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. Annals of Global Health, 2020, 86, 81.	0.8	12
27	DNGR1-mediated deletion of A20/Tnfaip3 in dendritic cells alters T and B-cell homeostasis and promotes autoimmune liver pathology. Journal of Autoimmunity, 2019, 102, 167-178.	3.0	14
28	Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion. Viruses, 2019, 11, 687.	1.5	7
29	PS-154-Dissecting the different roles of ORF3 in HEV spread and fecal shedding in a humanized mouse model. Journal of Hepatology, 2019, 70, e97.	1.8	1
30	Biobanking for Viral Hepatitis Research. Frontiers in Medicine, 2019, 6, 183.	1.2	4
31	FRI-153-Potent hepatitis B core-specific B cell responses associate with clinical parameters in untreated and virally suppressed chronic HBV patients. Journal of Hepatology, 2019, 70, e455.	1.8	1
32	Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up. BMC Public Health, 2019, 19, 39.	1.2	16
33	Sustained offâ€treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced <scp>HB</scp> eAg seroconversion. Journal of Viral Hepatitis, 2019, 26, 766-769.	1.0	7
34	Hepatitis E Virus Shows More Genomic Alterations in Cell Culture than In Vivo. Pathogens, 2019, 8, 255.	1.2	8
35	8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 2019, 70, 554-557.	1.8	4
36	Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after <scp>HB</scp> eAg seroconversion is associated with high relapse rates and fatal outcomes. Alimentary Pharmacology and Therapeutics, 2018, 47, 1170-1180.	1.9	45

#	Article	IF	Citations
37	Assessment of biopsyâ€proven liver fibrosis by twoâ€dimensional shear wave elastography: An individual patient dataâ€based metaâ€analysis. Hepatology, 2018, 67, 260-272.	3.6	322
38	Clinical and virological heterogeneity of hepatitis delta in different regions worldâ€wide: The Hepatitis Delta International Network (<scp>HDIN</scp>). Liver International, 2018, 38, 842-850.	1.9	72
39	TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands. Antiviral Research, 2018, 157, 27-37.	1.9	16
40	Focus on the liver: Host–virus interactions in HBV. Journal of Hepatology, 2017, 66, 884-885.	1.8	2
41	Belgian experience with direct acting antivirals in people who inject drugs. Drug and Alcohol Dependence, 2017, 177, 214-220.	1.6	31
42	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. Clinical Infectious Diseases, 2017, 65, 680-683.	2.9	30
43	Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Scientific Reports, 2017, 7, 8267.	1.6	36
44	Shearâ€wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. Liver International, 2017, 37, 396-405.	1.9	113
45	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARI±-regulated dermatopontin. JCI Insight, 2017, 2, .	2.3	96
46	Unique intrahepatic transcriptomics profiles discriminate the clinical phases of a chronic HBV infection. PLoS ONE, 2017, 12, e0179920.	1.1	19
47	Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS ONE, 2017, 12, e0170933.	1.1	8
48	Passenger Lymphocyte Syndrome (PLS): A Single-center Retrospective Analysis of Minor ABO-incompatible Liver Transplants. Journal of Clinical and Translational Hepatology, 2017, 5, 9-15.	0.7	14
49	Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8271.	1.4	33
50	Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism. Journal of Virology, 2016, 90, 6187-6199.	1.5	39
51	Liver Fibrosis Evaluation Using Realâ€time Shear Wave Elastography in Hepatitis C–Monoinfected and Human Immunodeficiency Virus/Hepatitis C–Coinfected Patients. Journal of Ultrasound in Medicine, 2016, 35, 1299-1308.	0.8	18
52	Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness. Hepatology, 2016, 64, 1809-1810.	3.6	22
53	Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. Journal of Virology, 2016, 90, 4394-4401.	1.5	73
54	Liver Monocytes and Kupffer Cells Remain Transcriptionally Distinct during Chronic Viral Infection. PLoS ONE, 2016, 11, e0166094.	1.1	7

#	Article	IF	CITATIONS
55	Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct. Journal of Virology, 2015, 89, 4809-4817.	1.5	37
56	CD4+CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. Journal of Hepatology, 2015, 62, 303-310.	1.8	51
57	Reâ€evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology, 2015, 62, 87-100.	3.6	96
58	Reversible severe hepatitis in anorexia nervosa. European Journal of Gastroenterology and Hepatology, 2014, 26, 473-477.	0.8	15
59	<i>ln vivo</i> evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology, 2011, 53, 755-762.	3.6	115
60	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. Journal of Hepatology, 2010, 53, 468-476.	1.8	68
61	Experimental models for hepatitis C viral infection. Hepatology, 2009, 50, 1646-1655.	3.6	72
62	Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver–chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology, 2008, 47, 1846-1855.	3.6	124
63	Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology, 2008, 48, 1761-1768.	3.6	200
64	Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity. Journal of Virology, 2007, 81, 3162-3169.	1.5	139
65	Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet, The, 2007, 370, 580-589.	6.3	474
66	Ultra-Rapid Cardiotoxicity of the Hepatitis C Virus Protease Inhibitor BILN 2061 in the Urokinase-Type Plasminogen Activator Mouse. Gastroenterology, 2007, 133, 1144-1155.	0.6	57
67	Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3805-3809.	3.3	408